Different genomic alterations in DNA damage repair (DDR) pathways occur in 20% to 25% of advanced prostate cancer, including homologous recombination repair (HRR) gene alterations. Identifying the ...
Breast cancer is the most frequently diagnosed malignancy worldwide. Inhibiting PARP-mediated DNA repair has emerged as a ...
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous ...
Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone Outcomes data for DNA-damaging ...
Therapeutic landscape of Rad51 in cancer treatment. Key elements include (1) DNA damage sources (PARPi, chemo/radiotherapy);(2) repair pathways (Rad51‐mediated HR); (3) intervention strategies (Rad51 ...
SAN DIEGO – The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair ...
A recent study, undertaken by researchers at the Tokyo Metropolitan University and the Tokyo Metropolitan Institute of Medical Science (both Japan), unravels key steps in the process of homologous ...
A major advance in cell biology has revealed how our cells safeguard their genetic material during one of the most vulnerable moments in their life cycle. The study identifies a specific protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results